Lenalidomide maintenance delayed CLL progression but not death in CLL6

Two years of maintenance treatment with lenalidomide delayed the progression of chronic lymphocytic leukaemia in patients who still had detectable disease after initial chemotherapy, but it did not help them live longer and came at the cost of more infections and low blood counts, according to the final analysis of the phase 3 CLL6 RESIDUUM trial [s1]. It is a result that illustrates one of the recurring tensions in cancer medicine: a treatment can clearly move an intermediate measure while leaving the outcome patients care most about unchanged.

Most people treated for chronic lymphocytic leukaemia (CLL) do not reach the deepest responses — so-called measurable residual disease (MRD) negativity — and are left with low-level disease that eventually regrows. The question CLL6 asked was whether lenalidomide, an immune-modulating pill, could keep that residual disease in check if given as maintenance after standard immunochemotherapy.

What the trial did

CLL6 RESIDUUM was a randomised, multicentre phase 3 trial run in Australia and France by two academic cooperative groups, the ALLG and FILO, and registered as ACTRN12610000060044 [s1]. Its funding came from the drug's makers — Celgene and, later, Bristol Myers Squibb — a commercial interest worth keeping in view when weighing how the result is framed [s1].

Patients with CLL who still had residual disease after initial chemoimmunotherapy were randomly assigned to two years of daily lenalidomide maintenance or to observation [s1]. The primary endpoint was time to disease progression or death. Between May 2011 and January 2018, 143 patients were randomised: 71 to lenalidomide and 72 to observation [s1]. A companion study used the EORTC QLQ-C30 questionnaire to track quality of life, which started out similar in the two arms, with mean global health scores of 76.3 in the lenalidomide group and 72.1 in the observation group on a 0-to-100 scale [s2].

What it found

Lenalidomide clearly lengthened the time before the leukaemia progressed. Median progression-free survival was 64.6 months with the drug (95% confidence interval 47.7 to not reached) versus 42.4 months with observation (95% CI 32.3 to 61.6), a difference of about 22 months that reached statistical significance (P=0.039) [s1]. The benefit persisted for three years after maintenance was stopped, and more patients on lenalidomide reached MRD negativity, especially those who completed at least 20 maintenance cycles [s1].

But that did not translate into longer life: there was no difference in overall survival between the arms [s1]. And the drug was not free of cost. Lenalidomide caused more cytopenias — low blood counts — as well as more infections and gastrointestinal side effects [s1]. Reassuringly, there were no cases of acute lymphoblastic leukaemia, a second cancer that has been a concern with immunomodulatory maintenance in other settings [s1].

How to read it

The progression-free survival gain is real and statistically solid, and the durability of the effect after stopping treatment, together with the deeper MRD responses, makes a coherent biological story [s1]. The harder truth is that progression-free survival is a surrogate: it measures how long the disease is held down, not how long the patient lives, and in CLL — often a slow-moving disease in which many patients have effective later-line options — a delay in progression need not change overall survival at all. CLL6 shows exactly that pattern: a clear win on the intermediate endpoint, a flat line on survival [s1].

That is where the costs matter. More infections and cytopenias are not trivial in a population already immunocompromised by their leukaemia, and quality of life is part of the ledger — which is why the trial's companion analysis of patient-reported outcomes is worth as much attention as the progression curve [s1][s2]. The balance of a longer disease-free interval against added toxicity, with no survival gain, is the kind of trade-off that belongs to an informed patient, not a headline.

The CLL6 result also arrives in a treatment landscape that has shifted under it. Coverage has examined the FDA approval of a next-generation BCL2 inhibitor in mantle cell lymphoma and a bispecific antibody moving into first-line follicular lymphoma, part of a broader move toward targeted and time-limited regimens that reframe where older maintenance strategies fit.

What to watch

The open question is whether any subgroup — perhaps those who achieve MRD negativity, or who tolerate the full course — gains enough to justify maintenance in an era of targeted therapy [s1]. For now, CLL6 RESIDUUM says lenalidomide maintenance buys time without buying survival, and that the time comes with side effects a patient would feel.

This article describes research and is not medical advice. Treatment decisions in CLL belong with treating haematologists.

Sources

• Lenalidomide maintenance in CLL: final analysis of the phase III CLL6 RESIDUUM study — British Journal of Haematology, 20 September 2026
• Impact of lenalidomide consolidation on quality of life: ancillary study of CLL6-RESIDUUM — BMC Cancer, 16 April 2025